Cargando…
A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas
INTRODUCTION: Management of locally advanced, unresectable, or metastatic (adv/met) esophageal adenocarcinoma (EAC) follows clinical guidance for gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, evidence for these guidelines is based largely on patients with adv/met GC/GEJC,...
Autores principales: | Shankaran, Veena, Xiao, Hong, Bertwistle, David, Zhang, Ying, You, Min, Abraham, Pranav, Chau, Ian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854438/ https://www.ncbi.nlm.nih.gov/pubmed/33244736 http://dx.doi.org/10.1007/s12325-020-01567-9 |
Ejemplares similares
-
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
por: Abraham, Pranav, et al.
Publicado: (2020) -
Docetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follow‐Up
por: Rosenberg, Ari Joseph, et al.
Publicado: (2019) -
Comparing treatment and outcomes in advanced esophageal,
gastroesophageal junction, and gastric adenocarcinomas: a population-based
study
por: Pape, Marieke, et al.
Publicado: (2023) -
Real-World Outcomes and Factors Associated With the Second-Line
Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal
Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019) -
Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer
por: Chau, Ian, et al.
Publicado: (2019)